Mankind Pharma (NSE: MANKIND) and Zydus Lifesciences Ltd (NSE: ZYDUSLIFE) are both listed in the Medicinal Chemicals and Botanical Products industry. Mankind Pharma has a market capitalisation of ₹1,09,870 Cr and Zydus Lifesciences ₹1,19,651 Cr, as of 16 Nov 2026. Their P/E ratios are 57 and 24.1 respectively. Return on equity is 12.45% for Mankind Pharma and 18.32% for Zydus Lifesciences. Over one year, Mankind Pharma's share price is up 16.7% and Zydus Lifesciences's is up 26.0%.
| Metric | Mankind Pharma | Zydus Lifesciences |
|---|---|---|
| NSE Symbol | MANKIND | ZYDUSLIFE |
| BSE Code | 543904 | 532321 |
| Share Price | ₹2,640.00 | ₹1,189.90 |
| Market Cap | ₹1,09,870 Cr | ₹1,19,651 Cr |
| P/E Ratio | 57 | 24.1 |
| Return on Equity | 12.45% | 18.32% |
| Return on Assets | 6.31% | 8.13% |
| Dividend Yield | 0.08% | 0.08% |
| Beta (1Y) | 0.37 | 0.26 |
| 1-Year Price Change | +16.7% | +26.0% |
| 3-Month Price Change | +9.8% | +1.9% |
| 52-Week Range | ₹1,909.70 – ₹2,705.00 | ₹835.50 – ₹1,266.60 |
| Latest Quarter | Q2 FY27 | Q2 FY27 |
| Quarterly Revenue | ₹4,338 Cr | ₹7,910 Cr |
| Quarterly Net Profit | ₹716 Cr | ₹928 Cr |
| Net Margin | 16.5% | 11.7% |
| EPS (Basic, Quarter) | ₹17.23 | ₹9.28 |
| Results Basis | consolidated | consolidated |
| Headquarters | New Delhi, Delhi | Ahmedabad, Gujarat |
The figures sit side by side and are not ranked. Quarterly figures are in ₹ crore, parsed from each company's exchange filing (XBRL); the two companies' latest quarters can differ.
Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations and consumer healthcare products in India and internationally. The company develops pharmaceuticals for acute and chronic therapeutics in the areas of anti-infective, cardiovascular, gastrointestinal, gynaecology, anti-diabetic, dermatology, pain/analgesics, neuro/CNS, vitamins/minerals/nutrients, respiratory diseases, etc. It also provides consumer healthcare products, such as condoms, pregnancy detection kits, oral contraceptives, antacid powders, vitamin and mineral supplements, and anti-acne preparations…
Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally. It operates through two segments: Pharmaceuticals and Consumer Products. It offers active pharmaceutical ingredients, finished dosage formulations, generics, specialty, biosimilars, vaccines, novel products, consumer wellness and animal health products under the Everyuth, Nutralite, SugarFree, Complan, Glucon-D, and Nycil brands. The company also provides a pipeline of biological products in the areas of onco…
Zydus Lifesciences has a market capitalisation of ₹1,19,651 Cr, against ₹1,09,870 Cr for Mankind Pharma as of 16 Nov 2026, so the two are about the same size by market cap.
Mankind Pharma has a P/E of 57 and Zydus Lifesciences a P/E of 24.1 as of 16 Nov 2026.
Mankind Pharma has a return on equity of 12.45% and Zydus Lifesciences 18.32%.
Mankind Pharma's share price is up 16.7% over one year and Zydus Lifesciences's is up 26.0%.
Mankind Pharma reported revenue of ₹4,338 Cr and net profit of ₹716 Cr for Q2 FY27. Zydus Lifesciences reported revenue of ₹7,910 Cr and net profit of ₹928 Cr for Q2 FY27. Figures are parsed from each company's exchange filing.
Both are classified under Pharmaceuticals > Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products on FinBizNet.
No. The page lays the two companies' published figures side by side and draws no conclusion from them. It is descriptive market data, not investment advice.
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.